BridgeBio Pharma (BBIO) EBIAT (2019 - 2025)
Historic EBIAT for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$184.9 million.
- BridgeBio Pharma's EBIAT fell 1259.21% to -$184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$805.7 million, marking a year-over-year decrease of 8053.27%. This contributed to the annual value of -$543.3 million for FY2024, which is 1682.42% up from last year.
- As of Q3 2025, BridgeBio Pharma's EBIAT stood at -$184.9 million, which was down 1259.21% from -$183.8 million recorded in Q2 2025.
- BridgeBio Pharma's 5-year EBIAT high stood at -$2.6 million for Q2 2022, and its period low was -$267.4 million during Q4 2024.
- Moreover, its 5-year median value for EBIAT was -$161.0 million (2021), whereas its average is -$147.7 million.
- Per our database at Business Quant, BridgeBio Pharma's EBIAT surged by 9749.3% in 2022 and then crashed by 617991.4% in 2023.
- Over the past 5 years, BridgeBio Pharma's EBIAT (Quarter) stood at -$152.3 million in 2021, then rose by 7.69% to -$140.6 million in 2022, then dropped by 21.17% to -$170.3 million in 2023, then tumbled by 56.98% to -$267.4 million in 2024, then soared by 30.84% to -$184.9 million in 2025.
- Its EBIAT was -$184.9 million in Q3 2025, compared to -$183.8 million in Q2 2025 and -$169.6 million in Q1 2025.